From Brooklyn to Berlin, GLP-1 medications are reshaping the global conversation around weight management. What began as a clinical breakthrough has quickly evolved into a cultural moment, redefining not only how consumers approach weight management, but also what they expect from the wider health and nutrition industry.

For brands operating in this space, the shift is undeniable. GLP-1 therapies are not simply another trend to respond to; they are reframing the role of nutrition itself.

As pharmaceutical solutions become more visible and widely adopted, the question is no longer whether supplements have a place in the weight management category, but how they can demonstrate meaningful, credible value alongside them.

Subscribe to our newsletters to stay up to date with all our content.

Ahead of Vitafoods Europe’s weight management spotlight session (Thursday, May 7), we’re looking at how the GLP-1 era is redefining consumer needs, and how brands must respond to stake a claim in this rapidly evolving space.

Beyond Weight Loss: New Consumer Mindset

The rapid development of GLP-1 medications has been accompanied by an equally rapid rise in awareness and adoption. In Great Britain alone, around 1.6 million adults are now using these therapies, and across Europe interest continues to accelerate. In the U.S., adoption is even higher, with an estimated 13% of the population now using GLP-1 agonists.

Yet the real transformation is not just commercial, it is behavioral. Consumers are beginning to view weight management through a more clinical and outcomes-driven lens. Expectations are rising accordingly. Quick fixes and generic solutions are giving way to a demand for targeted, science-backed support that aligns with how the body is actually functioning during weight loss. This is where the opportunity for nutrition brands emerges.

Redefining the Role of Weight Management Supplements

GLP-1 therapies work by mimicking the glucagon-like peptide-1 hormone, altering appetite, satiety, and metabolic signaling. As a result, they change people’s day-to-day diets; eating patterns shift, and caloric intake often decreases. And when less becomes the norm, what’s in your diet starts to matter far more — bringing physiological priorities, like muscle preservation and micronutrient sufficiency, into sharper focus.

This context, coupled with the increasing accessibility of GLP-1 agonists, may mean that traditional weight-management supplements focused on fat burning or appetite suppression are less aligned with evolving consumer needs. Consumer confidence and understanding of these approaches are already mixed; half of users do not understand the evidence behind their effectiveness. But this recent shift creates a clear opportunity to refocus.

As GLP-1 therapies reduce appetite and intake, they highlight gaps in nutrition and functional support, creating a space where supplements can provide real, tangible value. In fact, according to some studies, GLP-1 drugs can help users reduce overall food intake by 20%, though key nutrients such as protein, fiber, and calcium can fall short.

Rather than competing with GLP-1 agonists’ mechanisms, supplements are being reimagined as an additional layer of support that helps stabilize and optimize the experience. The most compelling innovations are not those that attempt to replicate pharmaceutical effects, but those that respond to the gaps and consequences created by them.

For some consumers, this may mean addressing the important issue of nutritional adequacy as food intake declines. For others, it is about maintaining strength and physical resilience in the face of rapid weight loss. There is also growing curiosity around the gut-metabolism connection, and how the microbiome may influence broader metabolic outcomes in a way that complements GLP-1 pathways.

This emerging consumer group is looking for solutions that reflect their full range of needs during weight loss. So, in the GLP-1 era, supplements are no longer single-purpose products; they are becoming integrated, multi-functional tools that help consumers navigate the full complexity of their weight-management journey.

The Claims Challenge

In the face of such rapid growth, GLP-1-related claims are on the rise. According to Innova Market Insights, supplements making claims in this area grew by 124% between 2020 and 2025. But this is a new and evolving space, and companies looking to capitalize on the GLP-1 companion product boom should tread carefully, particularly when it comes to navigating regulations and communicating benefits safely.

Europe’s regulatory landscape is famously exacting, and for supplement brands in the GLP-1 era, it’s a double-edged sword. Claims that hint at drug-like effects or directly reference GLP-1 mechanisms (aka, “faux-zempic claims”) are off-limits.

Last year, the UK Advertising Standards Authority ruled against multiple food supplement ads after finding comparisons to prescription GLP‑1 injections implied medicinal effects and breached advertising rules for unauthorized health claims. Brands looking to succeed in Europe, therefore, must get creative — and precise — in how they communicate benefits.

This issue isn’t unique to weight management claims. For example, emerging evidence suggests that GLP-1 use can lead to digestive side effects in some users. There’s an opportunity, therefore, for gut health support tailored specifically to the needs of these users. But in Europe, even familiar positionings, such as “probiotics,” carry regulatory weight and must be substantiated before they can be used.

The U.S. presents a very different picture. Regulatory oversight is less prescriptive (the FDA does not pre-approve supplement claims, placing the burden of proof on manufacturers), and supplement marketers have more flexibility in describing metabolic or weight-management support — though claims must still avoid disease-treatment language. This regulatory environment also allows for more direct-to-consumer marketing and messaging across digital channels, provided claims remain truthful and non-medicinal.

Despite these different contexts, there is a consistent lesson: credibility and evidence are essential. After all, over a third of consumers say that scientific evidence is a must-have for their supplements. But the way this is demonstrated must match local expectations.

In Europe, pre-authorized claims, rigorous substantiation, and transparent communication are critical. In the U.S., flexibility in claims allows more direct messaging, but unsupported or misleading statements can still attract enforcement. By tailoring messaging and investing in credible science, brands can build trust and compliance across regulatory landscapes.

A Category at a Crossroads

The rise of GLP-1 therapies is not simply reshaping weight management; it is redefining the role of supplements within it. For brands in the weight management space, we are at an important crossroads where strategic choices will determine success: either doubling down on traditional positionings or pivoting toward complementary support within a broader ecosystem of care.

For brands moving down this route, realizing this potential requires evolving in line with the lived experience of GLP-1 users. This means moving beyond single-function solutions and addressing a wider set of needs, from nutritional adequacy and muscle preservation to metabolic health and resilience.

But scientific credibility is non-negotiable. Whether positioning benefits as complementary to GLP-1 therapies or addressing their downstream effects, messaging must remain precise, transparent, and firmly within regulatory boundaries.

Ultimately, success in the GLP-1 era will depend on a company’s ability to align innovation, evidence, and communication. Those who can do so have the chance to play a meaningful role in the future of weight management solutions.

Vitafoods Europe 2026’s Spotlight Sessions will explore what comes next for weight management and how brands can be part of the conversations defining the GLP-1 era. Find out more here.